Premium
Cytotoxic necrotizing factor 1 promotes bladder cancer angiogenesis through activating RhoC
Author(s) -
Guo Yaxiu,
Wang Jingyu,
Zhou Kaichen,
Lv Junqiang,
Wang Lei,
Gao Shan,
Keller Evan T.,
Zhang ZhiSong,
Wang Quan,
Yao Zhi
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201903266rr
Subject(s) - rhoc , angiogenesis , vascular endothelial growth factor , cancer research , bladder cancer , cancer , metastasis , medicine , biology , vegf receptors
Uropathogenic Escherichia coli (UPEC), a leading cause of urinary tract infections, is associated with prostate and bladder cancers. Cytotoxic necrotizing factor 1 (CNF1) is a key UPEC toxin; however, its role in bladder cancer is unknown. In the present study, we found CNF1 induced bladder cancer cells to secrete vascular endothelial growth factor (VEGF) through activating Ras homolog family member C (RhoC), leading to subsequent angiogenesis in the bladder cancer microenvironment. We then investigated that CNF1‐mediated RhoC activation modulated the stabilization of hypoxia‐inducible factor 1α (HIF1α) to upregulate the VEGF. We demonstrated in vitro that active RhoC increased heat shock factor 1 (HSF1) phosphorylation, which induced the heat shock protein 90α (HSP90α) expression, leading to stabilization of HIF1α. Active RhoC elevated HSP90α, HIF1α, VEGF expression, and angiogenesis in the human bladder cancer xenografts. In addition, HSP90α, HIF1α, and VEGF expression were also found positively correlated with the human bladder cancer development. These results provide a potential mechanism through which UPEC contributes to bladder cancer progression, and may provide potential therapeutic targets for bladder cancer.